Abstract:Introduction: Anti-sulfatide antibodies are key biomarkers for the diagnosis of Guillain–Barré syndrome (GBS). However, case reports on anti-sulfatide antibody-related GBS are rare, particularly for atypical cases. Case description, case 1: A 63 years-old man presented with limb numbness and diplopia persisting for 2 weeks, with marked deterioration over the previous 4 days. His medical history included cerebral infarction, diabetes, and coronary atherosclerotic cardiomyopathy. Physical examination revealed limited movement in his left eye and diminished sensation in his extremities. Initial treatments included antiplatelet agents, cholesterol-lowering drugs, hypoglycemic agents, and medications to improve cerebral circulation. Despite this, his condition worsened, resulting in bilateral facial paralysis, delirium, ataxia, and decreased lower limb muscle strength. Treatment with intravenous high-dose immunoglobulin and dexamethasone resulted in gradual improvement. A 1 month follow-up revealed significant neurological sequelae. Case description, case 2: A 53 years-old woman was admitted for adenomyosis and subsequently experienced sudden limb weakness, numbness, and pain that progressively worsened, presenting with diminished sensation and muscle strength in all limbs. High-dose intravenous immunoglobulin, vitamin B1, and mecobalamin were administered. At the 1 month follow-up, the patient still experienced limb numbness and difficulty walking. In both patients, albuminocytologic dissociation was found on cerebrospinal fluid (CSF) analysis, positive anti-sulfatide antibodies were detected in the CSF, and electromyography indicated peripheral nerve damage. Conclusion: Anti-sulfatide antibody-related GBS can present with Miller–Fisher syndrome, brainstem encephalitis, or a combination of the two, along with severe pyramidal tract damage and residual neurological sequelae, thereby expanding the clinical profile of this GBS subtype. Anti-sulfatide antibodies are a crucial diagnostic biomarker. Further exploration of the pathophysiological mechanisms is necessary for precise treatment and improved prognosis.

Antibodies to Glycolipids in Guillain-Barré Syndrome, Miller Fisher Syndrome and Related Autoimmune Neurological Diseases

Detection of anti-ganglioside antibodies in Guillain-Barré syndrome

Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants

Anti-sulfatide antibody-related Guillain–Barré syndrome presenting with overlapping syndromes or severe pyramidal tract damage: a case report and literature review

Atypical Guillain-Barré syndrome with positive anti-sulfatide, anti-GT1b, and anti-GT1a antibodies: A case report

Elevated Serum Level of IL-2,IL-2Ab,IFN-α and IFN-α Antibody in GBS

Anti-Ganglioside Antibodies In Guillain- Barre Syndrome And Chronic Inflammatory Demyelinating Polyneuropathy In Chinese Patients

Polycranial neuropathy and sensory ataxia with IgG anti-GD1a antibody as a variant of Guillain-Barré syndrome

Antiganglioside antibodies in neurological diseases

SARS-CoV-2-associated Guillain-Barré syndrome in four patients: what do we know about pathophysiology?

Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry

Only anti-GM4 antibody positivity in a Chinese girl with overlapping MFS/GBS: a case report

Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome

Campylobacter jejuni Infection, Anti-Ganglioside Antibodies, and Neuropathy

Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test

Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome

Ataxia and ophthalmoplegia: an atypical case of Miller Fisher syndrome (MFS) with anti-GAD antibody

Exploring Treatments for a Rare Guillain-Barré Variant: A Case Report of Miller-Fisher Syndrome

On-Membrane Dynamic Interplay between Anti-GM1 IgG Antibodies and Complement Component C1q

AntiGQ1b antibody positive with MFS/GBS overlapped syndrome with diplopia and hemiplegia onset: Case report and retrospective analysis

Potential biomarkers identified by tandem mass tags based quantitative proteomics for diagnosis and classification of Guillain–Barré syndrome